These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34631713)

  • 1. Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy.
    Zhong W; Li Y; Yuan Y; Zhong H; Huang C; Huang J; Lin Y; Huang J
    Front Cell Dev Biol; 2021; 9():736540. PubMed ID: 34631713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
    Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
    Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy
    Zhong W; Zhong H; Zhang F; Huang C; Lin Y; Huang J
    Front Mol Biosci; 2021; 8():684050. PubMed ID: 34250018
    [No Abstract]   [Full Text] [Related]  

  • 6. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
    Pan H; Lu W; Zhang M; Liu C
    Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients.
    Yao J; Liang Z; Duan L; G Y; Liu J; An G
    Heliyon; 2023 Jun; 9(6):e15925. PubMed ID: 37484396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling.
    Zhong W; Zhang F; Huang C; Lin Y; Huang J
    J Cancer; 2021; 12(8):2359-2370. PubMed ID: 33758612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of molecular subtypes and diagnostic model in clear cell renal cell carcinoma based on collagen-related genes may predict the response of immunotherapy.
    Hong Y; Lv Z; Xing Z; Xu H; Chand H; Wang J; Li Y
    Front Pharmacol; 2024; 15():1325447. PubMed ID: 38375034
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of Epithelial-Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma.
    Zhong W; Zhang F; Huang C; Lin Y; Huang J
    Front Oncol; 2020; 10():591254. PubMed ID: 33324563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.
    Yang C; Yu T; Li Q; Xie F; Lin Q
    Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature.
    Liu G; Li F; Ge Y; Shi Y; Ren F; Zhu L
    J Cancer; 2023; 14(17):3335-3350. PubMed ID: 37928426
    [No Abstract]   [Full Text] [Related]  

  • 17. Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma.
    Jiang A; Meng J; Bao Y; Wang A; Gong W; Gan X; Wang J; Bao Y; Wu Z; Lu J; Liu B; Wang L
    Front Oncol; 2021; 11():755212. PubMed ID: 34804944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.